Cancer drug repurposed for lung scarring in early safety trial
NCT ID NCT05515627
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 33 times
Summary
This early-stage study tests whether atezolizumab, a drug used for cancer, is safe for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring. About 24 adults aged 50 and older with confirmed IPF will receive the drug. Researchers will track side effects and check if the drug helps stabilize lung function and reduce scarring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
Conditions
Explore the condition pages connected to this study.